Takashi Yoshioka

Summary

Affiliation: Tohoku University
Country: Japan

Publications

  1. ncbi request reprint FDG PET evaluation of residual masses and regrowth of abdominal lymph node metastases from colon cancer compared with CT during chemotherapy
    T Yoshioka
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    Clin Nucl Med 24:261-3. 1999
  2. ncbi request reprint Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation
    Takashi Yoshioka
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4 1 Seiryo machi, Aoba ku, Sendai 980 8575, Japan
    Int J Clin Oncol 11:454-60. 2006
  3. ncbi request reprint Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer
    Takashi Yoshioka
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    J Nucl Med 44:690-9. 2003
  4. ncbi request reprint [A case of malignant melanoma from the esophagus responding to weekly paclitaxel therapy]
    Yuichi Kakudo
    Dept of Clinical Oncology, Institute of Development, Aging and Cancer and Tohoku University Hospital, Tohoku University
    Gan To Kagaku Ryoho 33:969-72. 2006
  5. ncbi request reprint [Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer]
    Natsuko Chiba
    Dept of Clinical Oncology, Institute of Development, Aging and Cancer and Tohoku University Hospital, Tohoku University
    Gan To Kagaku Ryoho 32:991-5. 2005
  6. ncbi request reprint AFP-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastasis responding to paclitaxel/CDDP: a case report
    Natsuko Chiba
    Department of Clinical Oncology, Institute of Development, Aging and Cancer IDAC, Tohoku University Hospital, Tohoku University, Sendai, Japan
    Anticancer Res 25:2965-8. 2005
  7. doi request reprint Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus
    Hisanori Ariga
    Department of Radiation Oncology, Tohoku University School of Medicine, Sendai, Japan
    Int J Radiat Oncol Biol Phys 75:348-56. 2009
  8. doi request reprint Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients
    Shunsuke Kato
    Institute of Development, Department of Clinical Oncology, Aging and Cancer, Tohoku University, Sendai, Japan
    Oncology 83:101-7. 2012
  9. ncbi request reprint FDG PET and gallium scintigraphy for diagnosis of an advanced jejunal adenocarcinoma with distant metastases
    Gengo Yamaura
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University Hospital, Sendai, Japan
    Clin Nucl Med 29:825-7. 2004
  10. ncbi request reprint Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer
    Takashi Yoshioka
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4 1 Seiryo machi, Aoba ku, Sendai 980 8575, Japan
    Gastric Cancer 6:153-8. 2003

Collaborators

Detail Information

Publications16

  1. ncbi request reprint FDG PET evaluation of residual masses and regrowth of abdominal lymph node metastases from colon cancer compared with CT during chemotherapy
    T Yoshioka
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    Clin Nucl Med 24:261-3. 1999
    ..F-18 FDG PET tumor images changed in accordance with the clinical progress, whereas CT findings were relatively unchanged. This case clearly shows the utility of F-18 FDG PET for follow-up during cancer chemotherapy...
  2. ncbi request reprint Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation
    Takashi Yoshioka
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4 1 Seiryo machi, Aoba ku, Sendai 980 8575, Japan
    Int J Clin Oncol 11:454-60. 2006
    ..We conducted a dose-escalation study of docetaxel and nedaplatin as second line-chemotherapy after definitive chemoradiation in patients with relapsed or refractory squamous cell carcinoma of the esophagus after chemoradiation...
  3. ncbi request reprint Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer
    Takashi Yoshioka
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    J Nucl Med 44:690-9. 2003
    ..The aim of this study was to evaluate the visual diagnostic accuracy of (18)F-FDG PET for advanced, metastatic, or recurrent gastric cancer and to generate semiquantitative values for lesions...
  4. ncbi request reprint [A case of malignant melanoma from the esophagus responding to weekly paclitaxel therapy]
    Yuichi Kakudo
    Dept of Clinical Oncology, Institute of Development, Aging and Cancer and Tohoku University Hospital, Tohoku University
    Gan To Kagaku Ryoho 33:969-72. 2006
    ..Weekly paclitaxel therapy was reasonably safe as reported in other reports and considered to be a promising regimen for malignant melanoma of the esophagus...
  5. ncbi request reprint [Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer]
    Natsuko Chiba
    Dept of Clinical Oncology, Institute of Development, Aging and Cancer and Tohoku University Hospital, Tohoku University
    Gan To Kagaku Ryoho 32:991-5. 2005
    ..These data suggest that 5-FU/l-LV can be given in the outpatient and yields improved prognosis and minimal adverse reactions even in patients in reduced dose or prolonged interval...
  6. ncbi request reprint AFP-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastasis responding to paclitaxel/CDDP: a case report
    Natsuko Chiba
    Department of Clinical Oncology, Institute of Development, Aging and Cancer IDAC, Tohoku University Hospital, Tohoku University, Sendai, Japan
    Anticancer Res 25:2965-8. 2005
    ..This is the first report, to our knowledge, of effective chemotherapy for liver metastases from an AFP-producing hepatoid adenocarcinoma of the esophagus...
  7. doi request reprint Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus
    Hisanori Ariga
    Department of Radiation Oncology, Tohoku University School of Medicine, Sendai, Japan
    Int J Radiat Oncol Biol Phys 75:348-56. 2009
    ....
  8. doi request reprint Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients
    Shunsuke Kato
    Institute of Development, Department of Clinical Oncology, Aging and Cancer, Tohoku University, Sendai, Japan
    Oncology 83:101-7. 2012
    ..We conducted a randomized phase II trial of modified leucovorin, fluorouracil and irinotecan (mFOLFIRI) + bevacizumab and sequential IRIS + bevacizumab as first- or second-line therapies...
  9. ncbi request reprint FDG PET and gallium scintigraphy for diagnosis of an advanced jejunal adenocarcinoma with distant metastases
    Gengo Yamaura
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University Hospital, Sendai, Japan
    Clin Nucl Med 29:825-7. 2004
  10. ncbi request reprint Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer
    Takashi Yoshioka
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4 1 Seiryo machi, Aoba ku, Sendai 980 8575, Japan
    Gastric Cancer 6:153-8. 2003
    ..We designed a biweekly administration regimen of TXT combined with CPT-11 for 4 weeks as one cycle in patients with inoperable or recurrent gastric cancer, and conducted a dose-escalation study...
  11. ncbi request reprint O-[18F]fluoromethyl-L-tyrosine is a potential tracer for monitoring tumour response to chemotherapy using PET: an initial comparative in vivo study with deoxyglucose and thymidine
    Gengo Yamaura
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4 1 Seiryo machi, Aoba Ward, Sendai 980 8575, Japan
    Eur J Nucl Med Mol Imaging 33:1134-9. 2006
    ..To compare the utility of a new artificial amino acid, O-[18F]fluoromethyl-L-tyrosine ([18F]FMT), for monitoring cancer chemotherapy with deoxyglucose and thymidine...
  12. doi request reprint In vitro and in vivo characterization of 2-deoxy-2-18F-fluoro-D-mannose as a tumor-imaging agent for PET
    Shozo Furumoto
    Department of Pharmacology, Graduate School of Medicine, Tohoku University, Sendai, Japan
    J Nucl Med 54:1354-61. 2013
    ....
  13. ncbi request reprint A novel germline mutation of the LKB1 gene in a patient with Peutz-Jeghers syndrome with early-onset gastric cancer
    Masanobu Takahashi
    Department of Clinical Oncology, Institute of Development, Aging and Cancer, and Tohoku University Hospital, Tohoku University, 4 1 Seiryo machi, Aoba ku, Sendai, 980 8575, Japan
    J Gastroenterol 39:1210-4. 2004
    ....
  14. ncbi request reprint Phase I-II study of biweekly paclitaxel administration with fixed-dose-rate cisplatin in advanced gastric cancer
    Kensei Yamaguchi
    Department of Gastroenterology, Saitama Cancer Center Hospital, Komuro 818, Ina machi, Saitama, 362 0806, Japan
    Gastric Cancer 9:36-43. 2006
    ..The aim of this phase I-II study was to determine the maximum tolerated dose (MTD) and to evaluate the toxicity and efficacy of combination chemotherapy with these two agents...
  15. ncbi request reprint [Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases]
    Satoshi Kato
    Dept of Clinical Oncology, Iwate Prefectural Central Hospital
    Gan To Kagaku Ryoho 34:1227-31. 2007
    ..Today several platinum-based combination chemotherapies are reported, but there is no large-scale randomized study. Because of its variety, individualized therapy may be ideal for CUP...
  16. ncbi request reprint A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703)
    Atsushi Ohtsu
    Division of Gastrointestinal Oncology Digestive Endoscopy, National Cancer Center Hospital East, Kashiwanoha, Kashiwa, Japan
    Jpn J Clin Oncol 33:28-32. 2003
    ....